肠道微生物群疗法：粪便微生物群移植与活体生物治疗产品。

IF 12.2 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Gut Microbes Pub Date : 2024-10-08 DOI:10.1080/19490976.2024.2412376

Do-Yeon Kim,So-Yeon Lee,Jae-Yun Lee,Tae Woong Whon,June-Young Lee,Che Ok Jeon,Jin-Woo Bae

{"title":"肠道微生物群疗法：粪便微生物群移植与活体生物治疗产品。","authors":"Do-Yeon Kim,So-Yeon Lee,Jae-Yun Lee,Tae Woong Whon,June-Young Lee,Che Ok Jeon,Jin-Woo Bae","doi":"10.1080/19490976.2024.2412376","DOIUrl":null,"url":null,"abstract":"The human intestine hosts a complex ecosystem of various microorganisms, collectively known as the gut microbiome, which significantly impacts human health. Disruptions in the gut microbiome are linked to various disorders, including gastrointestinal diseases, such as Clostridioides difficile infection and inflammatory bowel disease, as well as metabolic, neurological, oncologic conditions. Fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) have emerged as prospective therapeutic procedures to restore microbial and metabolic balance in the gut. This review assesses the latest advancements, challenges, and therapeutic efficacy of FMT and LBPs, highlighting the need for standardization, safety, and long-term evaluation to optimize their clinical application.","PeriodicalId":12909,"journal":{"name":"Gut Microbes","volume":"20 1","pages":"2412376"},"PeriodicalIF":12.2000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products.\",\"authors\":\"Do-Yeon Kim,So-Yeon Lee,Jae-Yun Lee,Tae Woong Whon,June-Young Lee,Che Ok Jeon,Jin-Woo Bae\",\"doi\":\"10.1080/19490976.2024.2412376\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The human intestine hosts a complex ecosystem of various microorganisms, collectively known as the gut microbiome, which significantly impacts human health. Disruptions in the gut microbiome are linked to various disorders, including gastrointestinal diseases, such as Clostridioides difficile infection and inflammatory bowel disease, as well as metabolic, neurological, oncologic conditions. Fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) have emerged as prospective therapeutic procedures to restore microbial and metabolic balance in the gut. This review assesses the latest advancements, challenges, and therapeutic efficacy of FMT and LBPs, highlighting the need for standardization, safety, and long-term evaluation to optimize their clinical application.\",\"PeriodicalId\":12909,\"journal\":{\"name\":\"Gut Microbes\",\"volume\":\"20 1\",\"pages\":\"2412376\"},\"PeriodicalIF\":12.2000,\"publicationDate\":\"2024-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gut Microbes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/19490976.2024.2412376\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut Microbes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19490976.2024.2412376","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

人体肠道内有一个由各种微生物组成的复杂生态系统，统称为肠道微生物组，它对人体健康有重大影响。肠道微生物群紊乱与各种疾病有关，包括艰难梭菌感染和炎症性肠病等肠胃疾病，以及代谢、神经和肿瘤疾病。粪便微生物群移植（FMT）和活体生物治疗产品（LBPs）已成为恢复肠道微生物和代谢平衡的前瞻性治疗方法。本综述评估了粪便微生物群移植和活体生物治疗产品的最新进展、挑战和疗效，强调了标准化、安全性和长期评估的必要性，以优化其临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products.

The human intestine hosts a complex ecosystem of various microorganisms, collectively known as the gut microbiome, which significantly impacts human health. Disruptions in the gut microbiome are linked to various disorders, including gastrointestinal diseases, such as Clostridioides difficile infection and inflammatory bowel disease, as well as metabolic, neurological, oncologic conditions. Fecal microbiota transplantation (FMT) and live biotherapeutic products (LBPs) have emerged as prospective therapeutic procedures to restore microbial and metabolic balance in the gut. This review assesses the latest advancements, challenges, and therapeutic efficacy of FMT and LBPs, highlighting the need for standardization, safety, and long-term evaluation to optimize their clinical application.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Gut Microbes Medicine-Microbiology (medical)

CiteScore

18.20

自引率

3.30%

发文量

196

审稿时长

10 weeks

期刊介绍： The intestinal microbiota plays a crucial role in human physiology, influencing various aspects of health and disease such as nutrition, obesity, brain function, allergic responses, immunity, inflammatory bowel disease, irritable bowel syndrome, cancer development, cardiac disease, liver disease, and more. Gut Microbes serves as a platform for showcasing and discussing state-of-the-art research related to the microorganisms present in the intestine. The journal emphasizes mechanistic and cause-and-effect studies. Additionally, it has a counterpart, Gut Microbes Reports, which places a greater focus on emerging topics and comparative and incremental studies.